Key result
Combined treatment with 10% D-glucose and L-NAME in rats exacerbated hypertension (39% increase in systolic blood pressure) and insulin resistance, causing vascular but not cardiac hypertrophy.
Why the study?
Does nitric oxide inhibition with L-NAME exacerbate hypertension, insulin resistance, and cardiovascular remodeling in glucose-fed rats?
Does nitric oxide inhibition with L-NAME exacerbate hypertension, insulin resistance, and cardiovascular remodeling in glucose-fed rats?
Inhibition of nitric oxide exacerbates hypertension, insulin resistance, and vascular hypertrophy in a rat model of glucose-induced metabolic syndrome.
L-NAME plus glucose worsens rat hypertension and vascular hypertrophy; hypothesis-generating for NO inhibition in metabolic syndrome, requires human validation.
To determine the contribution of nitric oxide (NO) in cardiovascular remodeling associated to hypertension and insulin resistance, male Sprague-Dawley rats received tap water supplemented or not (control), with 10% D-glucose (G) and/or 50 mg x kg(-1) x d(-1) L-NAME to inhibit NO synthase (G-LN or LN) for 4 weeks. Systolic blood pressure increased by 12%, 26%, and 39% with G, LN, and G-LN treatments, respectively. Hyperinsulinemia and insulin resistance (homeostasis model assessment index) occurred in G-treated rats (P < 0.05) and were further increased in G-LN (P < 0.01). Plasma adrenaline concentrations were markedly increased in all treated groups, especially in G-LN (P < 0.01), whereas noradrenaline was increased in G-treated rats only. Whereas no cardiac hypertrophy or fibrosis was detected, aortic hypertrophy occurred in LN and G-LN rats (P < 0.001) without smooth muscle hyperplasia. Superoxide anion formation was increased in the aorta of all treated groups (P < 0.01) and in the heart of LN (P < 0.05), but reduced nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase activity was not affected. In conclusion, the loss of the wide-range protective effects of NO, the increased vascular oxidative stress, and the sympathoadrenal hyperactivity are among the contributing factors leading to the exacerbation of hypertension and insulin resistance in G-LN. These factors were sufficient to cause vascular but not cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Pilon et al. (2009) studied Hypertension and insulin resistance. 10% D-glucose and/or L-NAME vs. Control (tap water) was evaluated on Systolic blood pressure, insulin resistance, and cardiovascular remodeling. Combined treatment with 10% D-glucose and L-NAME in rats exacerbated hypertension (39% increase in systolic blood pressure) and insulin resistance, causing vascular but not cardiac hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: